secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2021-12-06T23:59:59+00:00
Accession:  0001493152-21-030522
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma appoints Thomas Hoover as Chief Business Officer; $412k salary, 850k options
--------------------------------------------------------------------------------

- Thomas Hoover, 52, appointed Chief Business Officer effective December 6, 2021.
- Initial base salary of $412,000 with target bonus up to 40% of base.
- Grant of options to purchase 850,000 shares under 2013 Equity Incentive Plan.
- Previously Chief Business Officer at Millendo Therapeutics (NASDAQ: TPST) and VP at Sunovion.
- Newly created role to lead business development, strategic planning, and licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315221030522/0001493152-21-030522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315221030522/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-030522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer